NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Brokerages

NewAmsterdam Pharma (NASDAQ:NAMS) has been given an average recommendation of “Buy” by the six research firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $33.25.

A number of research firms recently commented on NAMS. TD Cowen started coverage on NewAmsterdam Pharma in a research note on Wednesday, May 15th. They issued a “buy” rating on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday.

Insider Activity

In related news, CEO Michael H. Davidson acquired 5,000 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was purchased at an average cost of $17.26 per share, with a total value of $86,300.00. Following the acquisition, the chief executive officer now owns 204,784 shares of the company’s stock, valued at approximately $3,534,571.84. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 19.50% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Parkman Healthcare Partners LLC lifted its holdings in NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after purchasing an additional 51,726 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in NewAmsterdam Pharma during the 1st quarter valued at about $5,407,000. Opaleye Management Inc. purchased a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $2,964,000. Jennison Associates LLC bought a new position in NewAmsterdam Pharma in the 1st quarter valued at $22,015,000. Finally, Janus Henderson Group PLC bought a new stake in NewAmsterdam Pharma during the first quarter valued at $15,018,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Down 1.4 %

NASDAQ NAMS opened at $17.02 on Monday. NewAmsterdam Pharma has a fifty-two week low of $5.63 and a fifty-two week high of $26.35. The firm’s fifty day moving average price is $19.01 and its two-hundred day moving average price is $20.38.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.08). The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $2.95 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -2.24 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.